Emerging role of the ubiquitin-proteasome system as drug targets

Current Pharmaceutical Design

Volumn 19, Issue 18, 2013, Pages 3175-3189

  Kar, Gozde ^a   Keskin, Ozlem ^a   Fraternali, Franca ^b   Gursoy, Attila ^a  

^a KOÇ UNIVERSITY   (Turkey)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Disease; Drug design; Ubiquitin proteosome system

Indexed keywords

ADENOSINE TRIPHOSPHATE; BORTEZOMIB; CARFILZOMIB; DELANZOMIB; IPSI 001; IXAZOMIB CITRATE; OPROZOMIB; PARKIN; PR 957; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN MDM2; RING FINGER PROTEIN; SALINOSPORAMIDE A; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

ARTICLE; DRUG TARGETING; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; DNA REPAIR; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UBIQUITIN;

EID: 84878887472     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319180002     Document Type: Article

References (210)

1. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006; 5: 596-613.
2. Pickart CM. Mechanisms underlying ubiquitination. Annu RevBiochem 2001; 70: 503-33.
3. Bennett EJ, Harper JW. DNA damage: ubiquitin marks the spot. Nat Struct Mol Biol 2008; 15: 20-2.
4. Hoeller D, Dikic I. Targeting the ubiquitin system in cancertherapy. Nature 2009; 458: 438-44.
5. Herrmann J, Ciechanover A, Lerman LO, Lerman A. Theubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res 2004; 61: 11-21.
6. Petroski MD. The ubiquitin system, disease, and drug discovery. BMC Biochem 2008; 9 Suppl 1: S7.
7. Lehman NL. The ubiquitin proteasome system in neuropathology. Acta Neuropathol 2009; 118: 329-47.
8. Hershko A, Ciechanover A. The ubiquitin system. Annu RevBiochem 1998; 67: 425-79.
9. Yang Y, Kitagaki J, Dai RM, et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res 2007; 67: 9472-81.
10. Xu GW, Ali M, Wood TE, et al. The ubiquitin-activating enzymeE1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 2010; 115: 2251-9.
11. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor ofNEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-6.
12. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009; 15: 3912-6.
13. van Ree JH, Jeganathan KB, Malureanu L, van Deursen JM. Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol 2010; 188: 83-100.
14. Hao J, Xu A, Xie X, et al. Elevated expression of UBE2T in lungcancer tumors and cell lines. Tumour Biol 2008; 29: 195-203.
15. Maeda H, Miyajima N, Kano S, et al. Ubiquitin-conjugatingenzyme UBE2Q2 suppresses cell proliferation and is downregulated in recurrent head and neck cancer. Mol Cancer Res 2009; 7: 1553-62.
16. Zhu S, Sachdeva M, Wu F, Lu Z, Mo YY. Ubc9 promotes breastcell invasion and metastasis in a sumoylation-independent manner. Oncogene 2010; 29: 1763-72.
17. Duan X, Trent JO, Ye H. Targeting the SUMO E2 conjugatingenzyme Ubc9 interaction for anti-cancer drug design. Anticancer Agents Med Chem 2009; 9: 51-4.
18. Wong BR, Parlati F, Qu K, et al. Drug discovery in the ubiquitinregulatory pathway. Drug Discov Today 2003; 8: 746-54.
19. Dominguez C, Bonvin AM, Winkler GS, et al. Structural model ofthe UbcH5B/CNOT4 complex revealed by combining NMR, mutagenesis, and docking approaches. Structure 2004; 12: 633-44.
20. Weissman AM. Themes and variations on ubiquitylation. Nat RevMol Cell Biol 2001; 2: 169-78.
21. Huang DT, Miller DW, Mathew R, et al. A unique E1-E2interaction required for optimal conjugation of the ubiquitin-like protein NEDD8. Nat Struct Mol Biol 2004; 11: 927-35.
22. Rotin D, Kumar S. Physiological functions of the HECT family ofubiquitin ligases. Nat Rev Mol Cell Biol 2009; 10: 398-409.
23. Borden KL. RING domains: master builders of molecularscaffolds? J Mol Biol 2000; 295: 1103-12.
24. Ohi MD, Vander Kooi CW, Rosenberg JA, Chazin WJ, Gould KL. Structural insights into the U-box, a domain associated with multiubiquitination. Nat Struct Biol 2003; 10: 250-5.
25. Cohen P, Tcherpakov M. Will the ubiquitin system furnish as manydrug targets as protein kinases? Cell 2010; 143: 686-93.
26. Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat JP. MDM2 gene amplification in human breast cancer. Eur J Cancer 1994; 30A: 982-4.
27. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 geneamplification database. Nucleic Acids Res 1998; 26: 3453-9.
28. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-8.
29. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds top53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-8.
30. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 2011; 10: 29-46.
31. Merlet J, Burger J, Gomes JE, Pintard L. Regulation of cullin-RING E3 ubiquitin-ligases by neddylation and dimerization. Cell Mol Life Sci 2009; 66: 1924-38.
32. Chen Q, Xie W, Kuhn DJ, et al. Targeting the p27 E3 ligaseSCF(Skp2) results in p27-and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008; 111: 4690-9.
33. Nakajima H, Fujiwara H, Furuichi Y, Tanaka K, Shimbara N. Anovel small-molecule inhibitor of NF-kappaB signaling. Biochem Biophys Res Commun 2008; 368: 1007-13.
34. Orlicky S, Tang X, Neduva V, et al. An allosteric inhibitor ofsubstrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol 2010; 28: 733-7.
35. Wu H, Tschopp J, Lin SC. Smac mimetics and TNFalpha: adangerous liaison? Cell 2007; 131: 655-8.
36. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity andpenetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-89.
37. Scully R. Role of BRCA gene dysfunction in breast and ovariancancer predisposition. Breast Cancer Res 2000; 2: 324-30.
38. Ohta T, Fukuda M. Ubiquitin and breast cancer. Oncogene 2004;23: 2079-88.
39. Dawson TM, Dawson VL. The role of parkin in familial andsporadic Parkinson's disease. Mov Disord 2010; 25 Suppl 1: S32-9.
40. Bedford L, Hay D, Devoy A, et al. Depletion of 26S proteasomesin mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 2008; 28: 8189-98.
41. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindaudisease. Lancet 2003; 361: 2059-67.
42. Maxwell PH, Wiesener MS, Chang GW, et al. The tumoursuppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5.
43. Kim WY, Kaelin WG. Role of VHL gene mutation in humancancer. J Clin Oncol 2004; 22: 4991-5004.
44. Sufan RI, Moriyama EH, Mariampillai A, et al. Oxygen-independent degradation of HIF-alpha via bioengineered VHL tumour suppressor complex. EMBO Mol Med 2009; 1: 66-78.
45. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505.
46. zur Hausen H. Papillomaviruses and cancer: from basic studies toclinical application. Nat Rev Cancer 2002; 2: 342-50.
47. Matsuura T, Sutcliffe JS, Fang P, et al. De novo truncatingmutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 1997; 15: 74-7.
48. Chen D, Kon N, Li M, et al. ARF-BP1/Mule is a critical mediatorof the ARF tumor suppressor. Cell 2005; 121: 1071-83.
49. Chen D, Brooks CL, Gu W. ARF-BP1 as a potential therapeutictarget. Br J Cancer 2006; 94: 1555-8.
50. Wang X, Trotman LC, Koppie T, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007; 128: 129-39.
51. Fouladkou F, Landry T, Kawabe H, et al. The ubiquitin ligaseNedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A 2008; 105: 8585-90.
52. Baker SJ. PTEN enters the nuclear age. Cell 2007; 128: 25-8.
53. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, DerynckR. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci U S A 2001; 98: 974-9.
54. Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligasemediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 2000; 275: 36818-22.
55. Fukuchi M, Fukai Y, Masuda N, et al. High-level expression of theSmad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 2002; 62: 7162-5.
56. Chen C, Zhou Z, Sheehan CE, et al. Overexpression of WWP1 isassociated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma. Int J Cancer 2009; 124: 2829-36.
57. Laine A, Ronai Z. Regulation of p53 localization and transcriptionby the HECT domain E3 ligase WWP1. Oncogene 2007; 26: 1477-83.
58. Singhal S, Taylor MC, Baker RT. Deubiquitylating enzymes anddisease. BMC Biochem 2008; 9 Suppl 1: S3.
59. Shi D, Grossman SR. Ubiquitin becomes ubiquitous in cancer:emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol Ther 2010; 10: 737-47.
60. Song MS, Salmena L, Carracedo A, et al. The deubiquitinylationand localization of PTEN are regulated by a HAUSP-PML network. Nature 2008; 455: 813-7.
61. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in thep53-Mdm2 pathway. Mol Cell 2004; 13: 879-86.
62. Li M, Chen D, Shiloh A, et al. Deubiquitination of p53 by HAUSPis an important pathway for p53 stabilization. Nature 2002; 416: 648-53.
63. Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C.Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 2012; 31: 2373-88.
64. Colland F, Formstecher E, Jacq X, et al. Small-molecule inhibitorof USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8: 2286-95.
65. Tian X, Isamiddinova NS, Peroutka RJ, et al. Characterization ofselective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format. Assay Drug Dev Technol 2011; 9: 165-73.
66. Mizuno E, Kobayashi K, Yamamoto A, Kitamura N, Komada M. Adeubiquitinating enzyme UBPY regulates the level of protein ubiquitination on endosomes. Traffic 2006; 7: 1017-31.
67. Colombo M, Vallese S, Peretto I, et al. Synthesis and biologicalevaluation of 9-oxo-9H-indeno [1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem 2010; 5: 552-8.
68. Niendorf S, Oksche A, Kisser A, et al. Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. Mol Cell Biol 2007; 27: 5029-39.
69. Graner E, Tang D, Rossi S, et al. The isopeptidase USP2a regulatesthe stability of fatty acid synthase in prostate cancer. Cancer Cell 2004; 5: 253-61.
70. Stevenson LF, Sparks A, Allende-Vega N, et al. Thedeubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 2007; 26: 976-86.
71. Allende-Vega N, Sparks A, Lane DP, Saville MK. MdmX is asubstrate for the deubiquitinating enzyme USP2a. Oncogene 2010; 29: 432-41.
72. Metzig M, Nickles D, Falschlehner C, et al. An RNAi screenidentifies USP2 as a factor required for TNF-alpha-induced NF-kappaB signaling. Int J Cancer 2011; 129: 607-18.
73. Popov N, Wanzel M, Madiredjo M, et al. The ubiquitin-specificprotease USP28 is required for MYC stability. Nat Cell Biol 2007; 9: 765-74.
74. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and asa target for cancer therapies. Adv Cancer Res 2010; 107: 163-224.
75. Anderson C, Crimmins S, Wilson JA, et al. Loss of Usp14 resultsin reduced levels of ubiquitin in ataxia mice. J Neurochem 2005; 95: 724-31.
76. Lee BH, Lee MJ, Park S, et al. Enhancement of proteasomeactivity by a small-molecule inhibitor of USP14. Nature 2010; 467: 179-84.
77. Murray RZ, Jolly LA, Wood SA. The FAM deubiquitylatingenzyme localizes to multiple points of protein trafficking in epithelia, where it associates with E-cadherin and beta-catenin. Mol Biol Cell 2004; 15: 1591-9.
78. Dupont S, Mamidi A, Cordenonsi M, et al. FAM/USP9x, adeubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009; 136: 123-35.
79. Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9Xstabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-7.
80. Nagai H, Noguchi T, Homma K, et al. Ubiquitin-like sequence inASK1 plays critical roles in the recognition and stabilization by USP9X and oxidative stress-induced cell death. Mol Cell 2009; 36: 805-18.
81. Cohn MA, Kowal P, Yang K, et al. A UAF1-containingmultisubunit protein complex regulates the Fanconi anemia pathway. Mol Cell 2007; 28: 786-97.
82. Masuya D, Huang C, Liu D, et al. The HAUSP gene plays animportant role in non-small cell lung carcinogenesis through p53-dependent pathways. J Pathol 2006; 208: 724-32.
83. Bignell GR, Warren W, Seal S, et al. Identification of the familialcylindromatosis tumour-suppressor gene. Nat Genet 2000; 25: 160-5.
84. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010; 17: 25-34.
85. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665-77.
86. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss ofthe cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424: 797-801.
87. Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumoursuppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-5.
88. Reiley WW, Jin W, Lee AJ, et al. Deubiquitinating enzyme CYLDnegatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 2007; 204: 1475-85.
89. Yoshida H, Jono H, Kai H, Li JD. The tumor suppressorcylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 2005; 280: 41111-21.
90. Klaus A, Birchmeier W. Wnt signalling and its impact ondevelopment and cancer. Nat Rev Cancer 2008; 8: 387-98.
91. Tauriello DV, Haegebarth A, Kuper I, et al. Loss of the tumorsuppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl. Mol Cell 2010; 37: 607-19.
92. Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination andubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430: 694-9.
93. Hitotsumatsu O, Ahmad RC, Tavares R, et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 2008; 28: 381-90.
94. Turer EE, Tavares RM, Mortier E, et al. Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J Exp Med 2008; 205: 451-64.
95. Duwel M, Welteke V, Oeckinghaus A, et al. A20 negativelyregulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 2009; 182: 7718-28.
96. Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifyingenzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5: 1052-60.
97. Mauro C, Pacifico F, Lavorgna A, et al. ABIN-1 binds toNEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J Biol Chem 2006; 281: 18482-8.
98. Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-inducedNF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289: 2350-4.
99. Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A 1996; 93: 6721-5.
100. Sierra MI, Wright MH, Nash PD. AMSH interacts with ESCRT-0to regulate the stability and trafficking of CXCR4. J Biol Chem 2010; 285: 13990-4004.
101. Glickman MH, Ciechanover A. The ubiquitin-proteasomeproteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
102. Dahlmann B. Role of proteasomes in disease. BMC Biochem 2007;8 Suppl 1: S3.
103. Karin M. Nuclear factor-kappaB in cancer development andprogression. Nature 2006; 441: 431-6.
104. Adams J. The development of proteasome inhibitors as anticancerdrugs. Cancer Cell 2004; 5: 417-21.
105. Gu H, Chen X, Gao G, Dong H. Caspase-2 functions upstream ofmitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008; 7: 2298-307.
106. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasomeinhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9: 1145-54.
107. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-91.
108. Zhou HJ, Aujay MA, Bennett MK, et al. Design and synthesis ofan orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009; 52: 3028-38.
109. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasomeinhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70: 1970-80.
110. Piva R, Ruggeri B, Williams M, et al. CEP-18770: A novel, orallyactive proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008; 111: 2765-75.
111. Dorsey BD, Iqbal M, Chatterjee S, et al. Discovery of a potent,selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008; 51: 1068-72.
112. Muchamuel T, Basler M, Aujay MA, et al. A selective inhibitor ofthe immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009; 15: 781-7.
113. Kuhn DJ, Hunsucker SA, Chen Q, et al. Targeted inhibition of theimmunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009; 113: 4667-76.
114. Feling RH, Buchanan GO, Mincer TJ, et al. Salinosporamide A: ahighly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 2003; 42: 355-7.
115. Chauhan D, Singh A, Brahmandam M, et al. Combination ofproteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008; 111: 1654-64.
116. Arkin MR, Wells JA. Small-molecule inhibitors of protein-proteininteractions: progressing towards the dream. Nat Rev Drug Discov 2004; 3: 301-17.
117. Chene P. Drugs targeting protein-protein interactions. ChemMedChem 2006; 1: 400-11.
118. Fry DC. Protein-protein interactions as targets for small molecule drug discovery. Biopolymers 2006; 84: 535-52.
119. Gonzalez-Ruiz D, Gohlke H. Targeting protein-protein interactions with small molecules: challenges and perspectives forcomputational binding epitope detection and ligand finding. Curr Med Chem 2006; 13: 2607-25.
120. Kar G, Kuzu G, Keskin O, Gursoy A. Protein-protein interfaces integrated into interaction networks: implications on drug design. Curr Pharm Des 2012;
121. Keskin O, Gursoy A, Ma B, Nussinov R. Towards drugs targeting multiple proteins in a systems biology approach. Curr Top MedChem 2007; 7: 943-51.
122. Zhao L, Chmielewski J. Inhibiting protein-protein interactions using designed molecules. Curr Opin Struct Biol 2005; 15: 31-4.
123. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. JMol Biol 1998; 280: 1-9.
124. Thorn KS, Bogan AA. ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions. Bioinformatics 2001; 17: 284-5.
125. Thanos CD, DeLano WL, Wells JA. Hot-spot mimicry of a cytokine receptor by a small molecule. Proc Natl Acad Sci U S A 2006; 103: 15422-7.
126. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping ofthe MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9: 2523-9.
127. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007; 450: 1001-9.
128. Christensen DE, Brzovic PS, Klevit RE. E2-BRCA1 RINGinteractions dictate synthesis of mono-or specific polyubiquitin chain linkages. Nat Struct Mol Biol 2007; 14: 941-8.
129. Christensen DE, Klevit RE. Dynamic interactions of proteins in complex networks: identifying the complete set of interacting E2sfor functional investigation of E3-dependent protein ubiquitination. FEBS J 2009; 276: 5381-9.
130. Gardner RG, Shearer AG, Hampton RY. In vivo action of the HRD ubiquitin ligase complex: mechanisms of endoplasmic reticulumquality control and sterol regulation. Mol Cell Biol 2001; 21: 4276-91.
131. Ballar P, Ors AU, Yang H, Fang S. Differential regulation of CFTRDeltaF508 degradation by ubiquitin ligases gp78 and Hrd1. Int J Biochem Cell Biol 2010; 42: 167-73.
132. van Wijk SJ, de Vries SJ, Kemmeren P, et al. A comprehensive framework of E2-RING E3 interactions of the human ubiquitin-proteasome system. Mol Syst Biol 2009; 5: 295.
133. Markson G, Kiel C, Hyde R, et al. Analysis of the human E2ubiquitin conjugating enzyme protein interaction network. Genome Res 2009; 19: 1905-11.
134. Zheng N, Wang P, Jeffrey PD, Pavletich NP. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 2000; 102: 533-9.
135. Kar G, Keskin O, Nussinov R, Gursoy A. Human proteome-scalestructural modeling of E2-E3 interactions exploiting interface motifs. J Proteome Res 2012; 11: 1196-207.
136. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: anetwork-based approach to human disease. Nat Rev Genet 2011; 12: 56-68.
137. Aloy P, Bottcher B, Ceulemans H, et al. Structure-based assemblyof protein complexes in yeast. Science 2004; 303: 2026-9.
138. Keskin O, Tsai CJ, Wolfson H, Nussinov R. A new, structurallynonredundant, diverse data set of protein-protein interfaces and its implications. Protein Sci 2004; 13: 1043-55.
139. Tuncbag N, Gursoy A, Nussinov R, Keskin O. Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat Protoc 2011; 6: 1341-54.
140. Aytuna AS, Gursoy A, Keskin O. Prediction of protein-proteininteractions by combining structure and sequence conservation in protein interfaces. Bioinformatics 2005; 21: 2850-5.
141. Tuncbag N, Keskin O, Gursoy A. HotPoint: hot spot predictionserver for protein interfaces. Nucleic Acids Res 2010; 38: W402-6.
142. Ye Y, Rape M. Building ubiquitin chains: E2 enzymes at work. NatRev Mol Cell Biol 2009; 10: 755-64.
143. Papaleo E, Ranzani V, Tripodi F, et al. An acidic loop and cognatephosphorylation sites define a molecular switch that modulates ubiquitin charging activity in Cdc34-like enzymes. PLoS Comput Biol 2011; 7: e1002056.
144. Autore F, Pagano B, Fornili A, Rittinger K, Fraternali F. In silicophosphorylation of the autoinhibited form of p47(phox): insights into the mechanism of activation. Biophys J 2010; 99: 3716-25.
145. Liu J, Nussinov R. Flexible cullins in cullin-RING E3 ligasesallosterically regulate ubiquitination. J Biol Chem 2011; 286: 40934-42.
146. Liu J, Nussinov R. Molecular dynamics reveal the essential role oflinker motions in the function of cullin-RING E3 ligases. J Mol Biol 2010; 396: 1508-23.
147. Patel S, George R, Autore F, et al. Molecular interactions ofASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res 2008; 36: 5139-51.
148. Patel S, Bui TT, Drake AF, Fraternali F, Nikolova PV. The p73DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding. Biochemistry 2008; 47: 3235-44.
149. Bruschweiler R. Protein dynamics: whispering within. Nat Chem2011; 3: 665-6.
150. Lakomek NA, Lange OF, Walter KF, et al. Residual dipolarcouplings as a tool to study molecular recognition of ubiquitin. Biochem Soc Trans 2008; 36: 1433-7.
151. Lange OF, Lakomek NA, Fares C, et al. Recognition dynamics upto microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Science 2008; 320: 1471-5.
152. Wlodarski T, Zagrovic B. Conformational selection and induced fitmechanism underlie specificity in noncovalent interactions with ubiquitin. Proc Natl Acad Sci U S A 2009; 106: 19346-51.
153. Long D, Bruschweiler R. In silico elucidation of the recognitiondynamics of ubiquitin. PLoS Comput Biol 2011; 7: e1002035.
154. Papaleo E, Casiraghi N, Arrigoni A, et al. Loop 7 of e2 enzymes:an ancestral conserved functional motif involved in the e2-mediated steps of the ubiquitination cascade. PLoS One 2012; 7: e40786.
155. Swaminathan G, Tsygankov AY. The Cbl family proteins: ringleaders in regulation of cell signaling. J Cell Physiol 2006; 209: 21-43.
156. Blake TJ, Shapiro M, Morse HC, 3rd, Langdon WY. Thesequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline rich domain and a leucine zipper-like motif. Oncogene 1991; 6: 653-7.
157. Umebayashi K, Stenmark H, Yoshimori T. Ubc4/5 and c-Cblcontinue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation. Mol Biol Cell 2008; 19: 3454-62.
158. Makishima H, Cazzolli H, Szpurka H, et al. Mutations of e3ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009; 27: 6109-16.
159. Joazeiro CA, Wing SS, Huang H, et al. The tyrosine kinasenegative regulator c-Cbl as a RING-type, E2-dependent ubiquitin protein ligase. Science 1999; 286: 309-12.
160. Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
161. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAPantagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-81.
162. Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels ofapoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003; 63: 6815-24.
163. Imoto I, Tsuda H, Hirasawa A, et al. Expression of cIAP1, a targetfor 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 2002; 62: 4860-6.
164. Varfolomeev E, Vucic D. (Un)expected roles of c-IAPs inapoptotic and NFkappaB signaling pathways. Cell Cycle 2008; 7: 1511-21.
165. Flygare JA, Beresini M, Budha N, et al. Discovery of a potentsmall-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem 2012; 55: 4101-13.
166. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial proteinthat promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
167. Verhagen AM, Ekert PG, Pakusch M, et al. Identification ofDIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
168. Flygare JA, Fairbrother WJ. Small-molecule pan-IAP antagonists:a patent review. Expert Opin Ther Pat 2010; 20: 251-67.
169. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapyfor cancer in the post-genomic era. Nat Biotechnol 2012; 30: 679-92.
170. Sato K, Hayami R, Wu W, et al. Nucleophosmin/B23 is acandidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem 2004; 279: 30919-22.
171. Yu X, Fu S, Lai M, Baer R, Chen J. BRCA1 ubiquitinates itsphosphorylation-dependent binding partner CtIP. Genes Dev 2006; 20: 1721-6.
172. Starita LM, Horwitz AA, Keogh MC, et al. BRCA1/BARD1ubiquitinate phosphorylated RNA polymerase II. J Biol Chem 2005; 280: 24498-505.
173. Ma Y, Fan S, Hu C, et al. BRCA1 regulates acetylation andubiquitination of estrogen receptor-alpha. Mol Endocrinol 2010; 24: 76-90.
174. Esteller M, Silva JM, Dominguez G, et al. Promoterhypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-9.
175. Hogervorst FB, Nederlof PM, Gille JJ, et al. Large genomicdeletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003; 63: 1449-53.
176. Mishra A, Godavarthi SK, Jana NR. UBE3A/E6-AP regulates cellproliferation by promoting proteasomal degradation of p27. Neurobiol Dis 2009; 36: 26-34.
177. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 1998; 78: 129-39.
178. Sanduja S, Kaza V, Dixon DA. The mRNA decay factortristetraprolin (TTP) induces senescence in human papillomavirus transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. Aging (Albany NY) 2009; 1: 803-17.
179. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosisprotein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004; 14: 231-43.
180. Zhang Z, Wang H, Li M, et al. MDM2 is a negative regulator ofp21WAF1/CIP1, independent of p53. J Biol Chem 2004; 279: 16000-6.
181. Schlott T, Reimer S, Jahns A, et al. Point mutations and nucleotideinsertions in the MDM2 zinc finger structure of human tumours. J Pathol 1997; 182: 54-61.
182. Kim SS, Yoo NJ, Jeong EG, Kim MS, Lee SH. Expression ofNEDD4-1, a PTEN regulator, in gastric and colorectal carcinomas. APMIS 2008; 116: 779-84.
183. Dawson TM. Parkin and defective ubiquitination in Parkinson'sdisease. J Neural Transm Suppl 2006; 209-13.
184. Read MA, Brownell JE, Gladysheva TB, et al. Nedd8 modificationof cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Mol Cell Biol 2000; 20: 2326-33.
185. Oberg C, Li J, Pauley A, et al. The Notch intracellular domain isubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem 2001; 276: 35847-53.
186. Yada M, Hatakeyama S, Kamura T, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23: 2116-25.
187. Nateri AS, Riera-Sans L, Da Costa C, Behrens A. The ubiquitinligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 2004; 303: 1374-8.
188. Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-dependentubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001; 294: 173-7.
189. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR fordegradation and cooperates with PTEN in tumor suppression. Science 2008; 321: 1499-502.
190. Akhoondi S, Sun D, von der Lehr N, et al. FBXW7/hCDC4 is ageneral tumor suppressor in human cancer. Cancer Res 2007; 67: 9006-12.
191. Frescas D, Pagano M. Deregulated proteolysis by the F-boxproteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-49.
192. Shapira M, Ben-Izhak O, Linn S, et al. The prognostic impact ofthe ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005; 103: 1336-46.
193. Hershko DD. Oncogenic properties and prognostic implications ofthe ubiquitin ligase Skp2 in cancer. Cancer 2008; 112: 1415-24.
194. Kavsak P, Rasmussen RK, Causing CG, et al. Smad7 binds toSmurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000; 6: 1365-75.
195. Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma:implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther 2008; 8: 63-73.
196. Li Y, Zhou Z, Chen C. WW domain-containing E3 ubiquitinprotein ligase 1 targets p63 transcription factor for ubiquitin mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 2008; 15: 1941-51.
197. Chen C, Zhou Z, Guo P, Dong JT. Proteasomal degradation of theKLF5 transcription factor through a ubiquitin-independent pathway. FEBS Lett 2007; 581: 1124-30.
198. Li Y, Zhou Z, Alimandi M, Chen C. WW domain containing E3ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene 2009; 28: 2948-58.
199. Neil JR, Tian M, Schiemann WP. X-linked inhibitor of apoptosisprotein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem 2009; 284: 21209-17.
200. Galban S, Duckett CS. XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ 2010; 17: 54-60.
201. Carter BZ, Mak DH, Schober WD, et al. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosissignaling pathways in AML. Blood 2010; 115: 306-14.
202. Carter BZ, Mak DH, Schober WD, et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008; 111: 3742-50.
203. Cummings J, Ranson M, Lacasse E, et al. Method validation and preliminary qualification of pharmacodynamic biomarkersemployed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 2006; 95: 42-8.
204. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primarymediastinal B cell lymphoma. J Exp Med 2009; 206: 981-9.
205. Priolo C, Tang D, Brahamandan M, et al. The isopeptidase USP2aprotects human prostate cancer from apoptosis. Cancer Res 2006; 66: 8625-32.
206. Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damageresponse. Cell 2006; 126: 529-42.
207. Faustrup H, Bekker-Jensen S, Bartek J, Lukas J, Mailand N. USP7 counteracts SCFbetaTrCP-but not APCCdh1-mediated proteolysisof Claspin. J Cell Biol 2009; 184: 13-9.
208. van der Horst A, de Vries-Smits AM, Brenkman AB, et al. FOXO4 transcriptional activity is regulated by monoubiquitination andUSP7/HAUSP. Nat Cell Biol 2006; 8: 1064-73.
209. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008; 8: 835-50.
210. Deng S, Zhou H, Xiong R, et al. Over-expression of genes andproteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat 2007; 104: 21-30.